Orion Infusions (DHA:ORIONINFU) LT-Debt-to-Total-Asset: 0.01 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:ORIONINFU Orion Infusions Ltd DHA:ORIONINFU
81 GF Score
Price BDT291.20
GF Value BDT316.17
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Orion Infusions LT-Debt-to-Total-Asset?

Orion Infusions DHA:ORIONINFU +0.10% 81 LT-Debt-to-Total-Asset is 0.01 as of Mar. 2026. GuruFocus rates DHA:ORIONINFU with a GF Score™ of 81/100 and a GF Value™ of BDT316.17 (Fairly Valued). The stock has 3 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Orion Infusions's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.01.

Orion Infusions's long-term debt to total assets ratio increased from Mar. 2025 (0.01) to Mar. 2026 (0.01). It may suggest that Orion Infusions is progressively becoming more dependent on debt to grow their business.

Orion Infusions  (DHA:ORIONINFU) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Orion Infusions LT-Debt-to-Total-Asset Related Terms

Orion Infusions LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Orion Infusions's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orion Infusions LT-Debt-to-Total-Asset Chart

Orion Infusions Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 0.03 0.02 0.01 0.01

Orion Infusions Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 0.01
DHA:ORIONINFU
81GF Score
Orion Infusions Ltd DHA:ORIONINFU
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orion Infusions LT-Debt-to-Total-Asset Calculation

Orion Infusions's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jun. 2025 is calculated as

LT Debt to Total Assets (A: Jun. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Jun. 2025 )/Total Assets (A: Jun. 2025 )
=9.161/847.234
=0.01

Orion Infusions's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=11.038/825.815
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.01 mean?
Orion Infusions (DHA:ORIONINFU) has a LT-Debt-to-Total-Asset of 0.01 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Orion Infusions and its competitors.
Is Orion Infusions' LT-Debt-to-Total-Asset too high?
Orion Infusions' current LT-Debt-to-Total-Asset is 0.01. Overall, Orion Infusions has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Orion Infusions' LT-Debt-to-Total-Asset compare to ZTS and UTHR?
Orion Infusions' LT-Debt-to-Total-Asset of 0.01 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?
A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Orion Infusions and its competitors. Orion Infusions's current LT-Debt-to-Total-Asset is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Infusions stock overvalued right now?
Based on GuruFocus' analysis, Orion Infusions (DHA:ORIONINFU) is currently considered Fairly Valued. The stock's GF Value™ is BDT316.17, compared to a current price of BDT291.20 — trading 7.9% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.01. Orion Infusions' overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Orion Infusions (DHA:ORIONINFU), the current LT-Debt-to-Total-Asset is 0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orion Infusions (DHA:ORIONINFU) Overvalued in 2026?

Based on GuruFocus' analysis, Orion Infusions stock appears to be undervalued. The current stock price of BDT291.20 is trading 7.9% below its estimated GF Value™ of BDT316.17. GuruFocus considers Orion Infusions to be Fairly Valued.

Key valuation signals for DHA:ORIONINFU:

  • LT-Debt-to-Total-Asset: 0.01
  • GF Value™: BDT316.17 vs. price of BDT291.20 (7.9% below fair value)
  • GF Score™: 81/100 with 3 warning signs

No single metric tells the full story. See the DHA:ORIONINFU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Orion Infusions Business Description

Address 153-154 Tejgaon Industrial Area, Orion House, Dhaka, BGD, 1208
Orion Infusions Ltd is a pharmaceutical company engaged in the production of various types of intravenous fluids, rehydration solutions, electrolyte solutions, and solutions for acidosis, as well as Ranitidine I.V. infusion and anti-microbial products such as Ciprofloxacin I.V. and Metronidazole I.V. The Company's products include Dextrolac, Dextropac, Dextrosal, Dianak, Electro Dex, Fructose, Hartman, Intralipid, Manisol, Maprocin, Nidazyl, Orlev, Ortac, Plasmasol, Proliv, and Salpac. In addition, the Group operates across several sectors, including pharma and healthcare, power and energy, infrastructure development, real estate, cosmetics and toiletries, consumer products, textiles and garments, and home appliances. Geographically, the Company operates in Bangladesh.
81GF Score

Get the complete analysis for DHA:ORIONINFU

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT291.20
Price
BDT316.17
GF Value